Treatment of PD-1 Inhibitor in AIDS-associated PML
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
- Status
- COMPLETED
- Phase
- N/A
FPT155 in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
- Status
- RECRUITING
- Phase
- PHASE2
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2